Theresa A. Guise, M.D., FASBMR, FAAAS
Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine
Present Title & Affiliation
Dual/Joint/Adjunct Appointment
Professor and Member, Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center at Houston, Houston, Texas
Education & Training
Degree-Granting Education
| 1985 | University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, US, MD |
Postgraduate Training
| 1990-1992 | Research Fellow, Endocrinology and Metabolism, The University of Texas Health Science Center at San Antonio, San Antonio, Texas |
| 1989-1990 | Clinical Fellowship, Endocrinology and Metabolism, The University of Texas Health Science Center at San Antonio, San Antonio, Texas |
| 1985-1988 | Clinical Internship, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania |
| 1985-1988 | Clinical Residency, Internal Medicine, University of Pittsburgh Health Center, Pittsburgh, Pennsylvania |
Licenses & Certifications
| 1991 | American Board of Internal Medicine, Endocrinology, Metabolism and Diabetes |
| 1989 | Texas Medical Board License |
| 1988 | American Board of Internal Medicine |
| 1986 | National Board of Medical Examiners |
Experience & Service
Administrative Appointments/Responsibilities
Director, Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2023 - Present
Other Professional Positions
Jerry and Peg Throgmartin Professor of Oncology, Indiana University, Indianapolis, IN, 2009 - 2020
Gerald D. Aurbach Professor of Endocrinology, University of Virginia, Charlottesville, VA, 2002 - 2009
Zachry Chair for Translational Research, Institute for Drug Development, CTRC, 2001
Extramural Institutional Committee Activities
Member, General Oncology Chair Search Committee, The University of Texas MD Anderson Cancer Center, 2025 - 2026
Mentoring Connector, Academic Mentoring Council (AMC), The University of Texas MD Anderson Cancer Center, 2023 - Present
Member, Endowed Positions and Awards Committee, The University of Texas MD Anderson Cancer Center, 2022 - 2025
Chair, Metabolism and Nutrition Program (MeNu) Review Board, Van Andel Research Institute, 2022 - Present
Mentor, CPRIT TRIUMPH Postdoctoral Fellowship Training Grant, The University of Texas MD Anderson Cancer Center, 2021 - Present
Member, Experimental Therapeutics/Systems Biology Joint Department Chair Search, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, Multidisciplinary Research Advisory Committee, The University of Texas MD Anderson Cancer Center, 2021 - 2025
Member, Special Emphasis Panel to review Metastasis Research Network” (RFA-CA-20-029) U54 Specialized Centers of the Metastasis Research Network (MetNet), National Institutes of Health, 2021
Member, European Association for Cancer Research (EACR)-American Association for Cancer Research (AACR) Basic and Translational Research Conference 2020 with ASPIC: Tumor Microenvironment, European Association for Cancer Research, 2020
Chairperson, TME working group, Tumor Microenvironment Steering Committee, American Association For Cancer Research, 2019 - 2022
Member, Education Committee of the Scientific Program Committee, American Association For Cancer Research, 2019 - 2020
Member, Search Committee to select Cancer Center Director, Indiana University Simon Cancer Center, 2019
Member, Tumor Microenvironment (TME) Steering Committee, American Association For Cancer Research, 2017 - 2022
Member, Review Panel Grand Challenges Grants, Indiana University, 2015 - 2016
Member, External Scientific Advisory Board, Van Andel Research Institute, 2014 - Present
Member, Scientific Advisory Board, Novartis International AG, 2013 - 2015
Member, Committee to select the Founding Dean, Richard M. Fairbanks School of Public Health, IUPUI, 2012
Member, Scientific Advisory Council, Susan G. Komen Foundation, 2010 - 2016
Member, Physician Scientist Advisory Committee, Indiana University School of Medicine, 2010 - 2013
Member, Strategic Planning Research Committee, Indiana University School of Medicine, 2010 - 2012
Member, Scientific Advisory Committee, Institute of Molecular Medicine, 2008 - 2011
Chair, Skeletal Biology Structure & Regeneration Study Section, National Institutes of Health, 2007 - 2009
Member, Research Advisory Committee, University of Virginia School of Medicine, 2007 - 2009
Member, Committee to review reappointment of Dean, University of Virginia, 2006
Member, Scientific Advisory Board, ET-9, Ninth International Endothelin Meeting, 2005
Member, Skeletal Biology Structure & Regeneration Study Section, National Institutes of Health, 2004 - 2007
Member, Search Committee, Associate Dean for Clinical Research, University of Virginia, 2004
Chairman, Education Committee, American Society for Bone and Mineral Research, 2002 - 2005
Member, Howard Hughes Medical Institute Executive Committee, UTHSCSA, 2002
Co-Chairman, Program Committee, American Society for Bone and Mineral Research, 2001 - 2002
Clinic Advisor, American Running and Fitness Association, American Running and Fitness Association, 2000 - 2010
Reviewer, Special Emphasis Panel for Breast Cancer Insight Awards, National Institutes of Health, 2000
Member, Program Committee, American Society for Bone and Mineral Research, 2000
Member, Program Committee, 1999 Endocrine Society Meeting, 1999
Member, Competitive Research Enhancement Fund Review Committee, UTHSCA, 1998 - 2002
Member, Education Committee, American Society for Bone and Mineral Research, 1998 - 2002
Member, Internal Medicine Residency Selection Committee, UTHSCA, 1998 - 2001
Member, Program Committee for the 1997 Annual Meeting of the American Society for Bone and Mineral Research, American Society for Bone and Mineral Research, 1997
Reviewer, NASA Life Sciences Division Study Section, Bone/Muscle Biology Panel, NASA, 1997
Member, General Clinical Research Center Advisory Committee, UTHSCSA, 1996 - 2001
Member, Institutional Animal Care and Use Committee, UTHSCSA, 1996 - 2000
Reviewer, Study Section, United States Army Medical Research and Materiel Command, 1996
Member, Cancer Coordinating Committee, UTHSCSA, 1995 - 1997
Member, Medical School Strategic Planning Committee, UTHSCSA, UTHSCSA, 1995
Editorial Activities
Editor, Journal of Bone Oncology, 2015 - 2025
Associate Editor, Primer on the Metabolic Bone Diseases and Disorders of Mineral, 7th Edition, 2009 - 2015
Associate Editor, Journal of Bone and Mineral Research, 2007 - 2012
Editor/Service on Editorial Board(s), Bone, 2006 - 2009
Editor, Bone, 2006 - 2009
Editor/Service on Editorial Board(s), Endocrinology, 2004
Editorial Board, Journal of Bone and Mineral Research: The Official Journal of the American Society for Bone and Mineral Research, 2003 - 2008
Editor/Service on Editorial Board(s), Journal of Bone and Mineral Research, 2003 - 2008
Editor, Journal of Bone and Mineral Research, 2003 - 2008
Consulting Editor, The Journal of Clinical Investigation, 2002 - 2006
Editor, Journal of Clinical Endocrinology and Metabolism, 2001 - 2004
Editor/Service on Editorial Board(s), Journal of Clinical Endocrinology and Metabolism, 2001 - 2004
Editor, Clinical and Translational Science, 2001
Editorial Board, BoneKey, International Bone and Mineral Society, 1999 - 2003
Honors & Awards
| 2026 - Present | Elected Fellow, American Association for the Advancement of Sciences (AAAS) |
| 2026 | Distinguished Service Award, Cancer and Bone Society |
| 2025 | Excellence in Research Award, The European Calcified Tissue Society |
| 2022 - Present | Abell-Hanger Distinguished Professor, The University of Texas |
| 2021 | Haddad Memorial Lecture, University of Pennsylvania |
| 2020 - Present | Cancer Prevention Research Institute of Texas (CPRIT) Scholar, Cancer Prevention Research Institute of Texas (CPRIT) |
| 2020 | Stephen M. Krane Award, American Society for Bone and Mineral Research |
| 2020 | Elected Fellow, American Society for Bone and Mineral Research |
| 2020 | Louis V. Avioli Memorial Lecture, American Society for Bone and Mineral Research |
| 2019 | Presidential Address, Musculoskeletal Tumor Society |
| 2018 | Legends of Iroquois Academic Hall of Fame, Iroquois School District Foundation |
| 2017 | Philip S. Hench Distinguished Alumnus Award, University of Pittsburgh School of Medicine |
| 2012 | Paula Stern Achievement Award, American Society for Bone and Mineral Research |
| 2010 | Komen Scholar, Susan G. Komen Foundation |
| 2009 | 15th Annual Donal Coffey Lecture, Society for Basic Urologic Research |
| 2009 | Jerry and Peg Throgmartin Professor of Oncology, Indiana University |
| 2009 | Legacy Laureate, University of Pittsburgh |
| 2008 | Elected Member, Association of American Physicians |
| 2004 | Elected Member, American Society for Clinical Investigation |
| 2002 | Gerald D. Aurbach Professor of Endocrinology, Endowed Chair, University of Virginia |
| 2002 | Mellon Investigator, University of Virginia Cancer Center |
| 2000 | Young Investigator Award, Advances in Mineral Metabolism |
| 1999 | Fuller Albright Award, American Society for Bone and Mineral Research |
| 1999 | Academic Award, Breast Cancer Program, US Army Department of Defense |
| 1998 | Research Day Award, Junior Faculty |
| 1998 | Outstanding Investigator Award, International Bone and Calcium Institute |
| 1998 | Best Doctors in America, National |
| 1997 - Present | Best Doctors in America, Central Region |
| 1996 - 1997 | Best Doctors in America, Central Region |
| 1996 | FIRST Award, NIH |
| 1992 | Clinical Investigator Award, NIH |
| 1992 | New Investigator Award, Breast Cancer Program, US Army Department of Defense |
| 1991 | Associate Investigator, Veterans Administration |
| 1991 | National Research Service Award, NIH |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Bad to the Bone: Systemic effects of pathologic bone resorption. Invited. Neurobiology Seminar Series. Houston, Texas, US.
- 2025. Role of pathologic bone resorption on cognitive function: Implications for cancer and treatment. Invited. Cancer Neuroscience Scientific Retreat. Houston, Texas, US.
- 2021. Bad to the bone: Systemic effects of pathological bone destruction. Invited. MD Anderson Cancer Center. Houston, TX, US.
- 2020. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Gallick Laboratory Meeting, GU Oncology, MD Anderson Cancer Center. Houston, TX, US.
- 2019. Cancer, bone, muscle and metabolism: what’s the connection?. Invited. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
- 2018. Bone destruction: is there an effect on metabolism?. Invited. Bloomington, Indiana, US.
- 2017. Cancer-associated muscle dysfunction: what’s bone got to do with it?. Invited. Bloomington, Indiana, US.
- 2016. Effect of bone destruction on glucose homeostasis: Bone regulation of insulin secretion. Invited. Bloomington, Indiana, US.
- 2015. Cancer, bone and muscle: it’s all about the microenvironment. Invited. Bloomington, Indiana, US.
- 2014. Cancer-associated muscle dysfunction: role of the bone microenvironment. Invited. Bloomington, Indiana, US.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Bloomington, Indiana, US.
- 2011. Molecular mechanisms of bone metastases: implications for therapy. Invited. Bloomington, Indiana, US.
- 2010. Targeting the bone microenvironment to treat bone metastases: new drugs and new insight into old drugs. Invited. Medicine Grand Rounds. Bloomington, Indiana, US.
- 2009. Targeting the bone microenvironment to treat bone metastases: new drugs and new insight into old drugs. Invited. Endocrinology Grand Rounds. Bloomington, Indiana, US.
- 2008. TGFβ: Cancer, bone and beyond. Invited. Hematology/Oncology Grand Rounds and Cancer Center Seminar Series. Charlottesville, Virginia, US.
- 2003. Endothelins in malignant and normal bone remodeling. Invited. Charlottesville, Virginia, US.
- 2003. Molecular mechanisms of osteolytic metastases: Implications for therapy in 2003. Invited. Grand Rounds. Charlottesville, Virginia, US.
- 2001. Molecular mechanisms of bone metastases: Implications for therapy. Invited. Dept. Medicine Grand Rounds. San Antonio, Texas, US.
- 1999. Mechanisms of osteoblastic metastases to bone: role of endothelin-1. Invited. Grand Rounds.
- 1997. The role of TGFß in breast cancer metastasis to bone. Invited. University of Texas Health Science Center, San Antonio. San Antonio, TX, US.
- 1996. Insight into the role of calcium-sensing receptor in disorders of calcium and bone metabolism. Invited. Dept. Medicine Grand Rounds.
- 1995. Role of PTHrP in the pathogenesis of breast cancer-mediated bone metastases. Invited. University of Texas Health Science Center, San Antonio. San Antonio, TX, US.
- 1993. Animal models of hypercalcemia. Invited. University of Texas Health Science Center, San Antonio. San Antonio, TX, US.
- 1993. Hypercalcaemia of malignancy: From bedside to bench. Invited. Dept. Medicine Grand Rounds. San Antonio, Texas, US.
- 1993. Hypercalcaemia of malignancy: From bedside to bench. Invited. Dept. Medicine Grand Rounds.
Regional Presentations
- 2022. Challenging bone cases. Invited. Austin, US.
- 2022. Systemic effects of pathologic bone remodeling. Houston, Texas, US.
- 2018. Beyond Jaws: an Exposé on Shark s. Invited. Erie, PA, US.
- 2002. Disorders of calcium homeostasis. Invited. Grand Rounds. Victoria, TX, US.
- 1997. Parathyroid hormone-related protein (PTHrP)-(1-139) isoform is efficiently secreted in vitro and enhances breast cancer metastasis to bone in vivo. Conference. Texas Mineralized Tissue Society. Corpus Christi, TX, US.
- 1996. Treatment of osteoporosis: 1996 and Beyond. Conference. Texas Medical Association. San Antonio, TX, US.
- 1996. Breast cancer-mediated osteolysis: Role of PTHrP and TGFß. Invited. Department of Pharmacology Research Conference. Galveston, TX, US.
National Presentations
- 2026. Bad to the bone: Systemic effects of pathologic bone destruction. Invited. Pak Symposium: Cancer and Bone. Dallas, Texas, US.
- 2026. Systemic effects of pathologic bone resorption. Invited. CroSSTOC series, US.
- 2026. Bad to the bone: Systemic effects of pathologic bone destruction. Invited. Cancer & Bone Society Meeting. Tampa, Florida.
- 2026. Bad to the bone: Systemic effects of pathologic bone destruction. Invited. Laura Evans Memorial Breast Cancer Symposium. Ketchem, Idaho.
- 2026. Systemic effects of pathologic bone destruction. Invited. Symptom Science Webinar on Cancer and Bone Health. Bethesda, Maryland, US.
- 2024. Anabolic agents and patients with cancer. Is there a role in bone health?. Invited, US.
- 2024. Bad to the Bone: Systemic Effects of Pathologic Bone Resorption. Invited. Pathology Grand Rounds. Denver, Colorado, US.
- 2024. Use of anabolic agents to treat osteoporosis. Invited, New Mexico, US.
- 2023. Why Do Hormone-Dependent Cancers Love Bone?. Invited. Enodcrine Society Annual Meeting ENDO 2023. Chicago, IL, US.
- 2023. Systemic effects of bone destruction on muscle function. Invited. Chicago, Illinois, US.
- 2023. Bad to the bone: effects of pathologic bone destruction on muscle. Special Symposium. Invited. American Association for Cancer Research Annual Meeting. Orlando, FL, US.
- 2022. Breast cancer bone metastases and diabetes. Invited, California, US.
- 2022. Bad to the bone: Systemic effects of pathological bone destruction. Major Symposium: Bone Metastases. Invited. American Association for Cancer Research Annual Meeting. New Orleans, LA, US.
- 2021. Systemic consequences of pathologic bone remodeling in cancer and cancer treatment. Haddad Memorial Lecture, US.
International Presentations
- 2026. Bad to the Bone: Systemic effects of pathologic bone destruction. Invited. Breast Cancer Think Tank, BS.
- 2025. Mechanisms of bone loss in cancer-induced bone diseases. Invited. Sheffield, GB.
- 2025. Brain-bone connection Korean Society of Bone and Mineral Research Meeting. Visiting, KR.
- 2025. Effects of pathologic bone resorption on cognition. Invited, KR.
- 2025. Systemic effects of pathologic bone destruction on muscle function,. Invited, KR.
- 2025. Cancer-associated cachexia. Invited, AT.
- 2025. The bone and brain connection. Excellence in Research Award. Invited, AT.
- 2025. Bad to the Bone: Systemic effects of pathologic bone destruction. Invited, BB.
- 2024. Use of denosumab in breast cancer: Against the motion. Panelist, CA.
- 2024. Challenging cases. Invited, GB.
- 2023. Use of anabolic agents for bone health in cancer patients. Invited. Vancouver, CA.
- 2023. Bad to the bone: systemic effects of pathologic bone destruction. Invited. Rudolph Möbauer Colloquium. Heidelberg, DE.
- 2021. Cancer, bone and beyond: an integrated view of the bone microenvironment and pathologic bone resorption. Invited. Crick International Cancer Conference, the Francis Crick Institute. London, GB.
- 2021. Treatment of bone metastases. Invited. Buenos Aires, AR.
Grant & Contract Support
| Date: | 2026 - Present |
| Title: | MFSD14A Defines an Ammonium-Driven Bone Remodeling |
| Funding Source: | The Lawrence Family Bone Disease Program of Texas |
| Role: | Mentor |
| Date: | 2024 - 2026 |
| Title: | Mechanisms of anaplastic thyroid cancer bone metastasis and effects of combination therapies with bone-targeted treatments |
| Funding Source: | ATC Petrick Young Investigator Award |
| Role: | Mentor |
| Date: | 2023 - Present |
| Title: | Attenuating Myeloma-Induced Bone Loss and Preserving Muscle Function Utilizing Low Intensity Vibrations and Carfilzomib to Suppress Excess TGF-β in the Bone Marrow Microenvironment |
| Funding Source: | Bone Disease Program of Texas |
| Role: | Mentor |
| Date: | 2021 - 2026 |
| Title: | UT STARS Award |
| Funding Source: | University of Texas |
| Role: | PI |
| Date: | 2020 - 2027 |
| Title: | Cancer Research Prevention Institute of Texas (CPRIT) RR190108 Established Investigator Award |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR190108 |
| Date: | 2018 - Present |
| Title: | Role of bone marrow fat on breast cancer growth in bone |
| Funding Source: | Dive into the Pink |
| Role: | PI |
Selected Publications
Peer-Reviewed Articles
- Gaffney CM, Casaril AM, Mahmud I, Wei B, Jiang Y, Fiore NT, Liu J, Valadez KM, Kolb EA, Cherry FR, Shi L, Dunner K, Lorenzi PL, Reiken SR, Grace PM, Mahalingam R, Guise TA, Hodo CL, Shepherd AJ. Inflammatory Neuropathy in Mouse and Primate Models of Colorectal Cancer. Nature Communications. e-Pub 2026.
- Bagheri-Yarmand R, Pagnotti GM, Kidd JL, Ramirez DA, Trivedi T, Guerra L, Wang Z, Cruz LM, Moehle JM, Jebaraj YS, Wan X, Song JH, Bassett RL, Lin S, Hu MI, Sherman SI, Hofmann M, Guise TA. RET-driven osteoprotegerin expression links medullary thyroid cancer to osteoblastic bone metastases. Cell Reports Medicine, 2026. e-Pub 2026.
- Pagnotti GM, Trivedi T, Wright LE, John S, Murthy S, Pattyn RR, Willis MS, She Y, Suresh S, Touray AF, Thompson WR, Rubin CT, Mohammad KS, Guise TA. Low intensity vibration with zoledronate reduces musculoskeletal weakness and adiposity in estrogen deprived female mice. Nature Communications 17(1), 2026. e-Pub 2026. PMID: 41559081.
- Dondossola E, Patil M, Guise TA. Effects of Tumors and Cancer Therapy on Bone. Nature Review Cancer. e-Pub 2026.
- Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti GM, Dole NS, She Y, Suresh S, Hain BA, Regan J, Ofer R, Wright L, Robling A, Cao X, Alliston T, Marks AR, Waning DL, Mohammad KS, Guise TA. Targeting osteoclastic bone resorption to mitigate muscle dysfunction: role of TGFbeta-mediated oxidative stress. Nature Communications. e-Pub 2026.
- Patil MD, Wangsiricharoen S, Lazar A, Moon BS, Madewell JE, Collins MT, Guise TA. Approach to determining etiology of hypophosphatemia in a patient with coexisting phosphaturic mesenchymal tumor and fibrous dysplasia. JBMR Plus 9(1), 2025. e-Pub 2025. PMID: 39664934.
- Tame-Elorduy, A, Szabo Yamashita, T, Perrier, ND, Lui, MS, Guise, TA. Normocalcemic Hyperparathyroidism:193-198, 2025. e-Pub 2025.
- Seibert, T, Shi, L, Althouse, S, Hoffman, R, Schneider, BP, Russ, KA, Altherr, CA, Warden, SJ, Guise, TA, Coggan, AR, Ballinger, TJ. Molecular and clinical effects of aromatase inhibitor therapy on skeletal muscle function in early-stage breast cancer. Scientific reports 14(1), 2024. e-Pub 2024. PMID: 38200207.
- Plett, PA, Chua, HL, Wu, T, Sampson, CH, Guise, TA, Wright, LE, Pagnotti, GM, Feng, H, Chin-Sinex, HJ, Pike, F, Cox, GN, MacVittie, TJ, Sandusky, GE, Orschell, CM. Effect of Age at Time of Irradiation, Sex, Genetic Diversity, and Granulopoietic Cytokine Radiomitigation on Lifespan and Lymphoma Development in Murine H-ARS Survivors. Radiation research 202(3):580-598, 2024. e-Pub 2024. PMID: 39099001.
- Boire, A, Burke, K, Cox, TR, Guise, TA, Jamal-Hanjani, M, Janowitz, T, Kaplan, RN, Lee, R, Swanton, C, Heiden, MG, Sahai, E. Why do patients with cancer die?. Nature Reviews Cancer 24(8):578-589, 2024. e-Pub 2024. PMID: 38898221.
- Yang, HS, Pan, W, Wang, Y, Zaydman, MA, Spies, NC, Zhao, Z, Guise, TA, Meng, QH, Wang, F. Generalizability of a Machine Learning Model for Improving Utilization of Parathyroid Hormone-Related Peptide Testing across Multiple Clinical Centers. Clinical chemistry 69(11):1260-1269, 2023. e-Pub 2023. PMID: 37738611.
- Liu, Y, Reiken, S, Dridi, H, Yuan, Q, Mohammad, KS, Trivedi, T, Miotto, MC, Wedderburn-Pugh, K, Sittenfeld, L, Kerley, Y, Meyer, JA, Peters, JS, Persohn, SA, Bedwell, AA, Figueiredo, LL, Suresh, S, She, Y, Soni, RK, Territo, PR, Marks, AR, Guise, TA. Targeting ryanodine receptor type 2 to mitigate chemotherapy-induced neurocognitive impairments in mice. Science translational medicine 15(715), 2023. e-Pub 2023. PMID: 37756377.
- Trivedi T, Manaa M, John S, Reiken S, Murthy S, Pagnotti GM, Dole NS, She Y, Suresh S, Hain BA, Regan J, Ofer R, Wright L, Robling A, Cao X, Alliston T, Marks AR, Waning DL, Mohammad KS, Guise TA. Zoledronic acid improves bone quality and muscle function in a high bone turnover state. bioRxiv, 2023. e-Pub 2023. PMID: 37333318.
- Pagnotti GM, Trivedi T, Wright LE, John SK, Murthy S, Pattyn RR, Willis MS, She Y, Suresh S, Thompson WR, Rubin CT, Mohammad KS, Guise TA. Low-Magnitude Mechanical Signals Combined with Zoledronic Acid Reduce Musculoskeletal Weakness and Adiposity in Estrogen-Deprived Mice. bioRxiv, 2023. e-Pub 2023. PMID: 36993656.
- Lui MS, Clemente-Gutierrez U, Vodopivec DM, Chang SL, Shirali AS, Huang BL, Chiang YJ, Fisher SB, Grubbs EG, Guise, TA, Graham PH, Perrier ND. Parathyroidectomy for Normocalcemic Primary Hyperparathyroidism is Associated with Improved Bone Mineral Density Regardless of Postoperative Parathyroid Hormone Levels. World J Surg 47(2):363-370, 2023. e-Pub 2023. PMID: 36195677.
- Calvert RD, Fleet JC, Fournier PGJ, Juarez P, Burcham GN, Haverkamp JM, Guise, TA, Ratliff TL, Elzey BD. Monocytic Myeloid-Derived Suppressor Cells from Tumor Tissue Are a Differentiated Cell with Limited Fate Plasticity. Immunohorizons 6(12):790-806, 2022. e-Pub 2022. PMID: 36480485.
- Roberts G, Benusiglio PR, Bisseling T, Coit D, Davis JL, Grimes S, Guise, TA, Hardwick R, Harris K, Mansfield PF, Rossaak J, Schreiber KC, Stanich PP, Strong VE, Kaurah P, Group LS. International Delphi consensus guidelines for follow-up after prophylactic total gastrectomy: the Life after Prophylactic Total Gastrectomy (LAP-TG) study. Gastric Cancer 25(6):1094-1104, 2022. e-Pub 2022. PMID: 35831514.
- Arellano DL, Juárez P, Verdugo-Meza A, Almeida-Luna PS, Corral-Avila JA, Drescher F, Olvera F, Jiménez S, Elzey BD, Guise, TA, Fournier PGJ. Bone Microenvironment-Suppressed T Cells Increase Osteoclast Formation and Osteolytic Bone Metastases in Mice. J Bone Miner Res 37(8):1446-1463, 2022. e-Pub 2022. PMID: 35635377.
- Liu H, He J, Bagheri-Yarmand R, Li Z, Liu R, Wang Z, Bach DH, Huang YH, Lin P, Guise, TA, Gagel RF, Yang J. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma. Nat Commun 13(1):3684, 2022. e-Pub 2022. PMID: 35760800.
- Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. Reply. N Engl J Med 386(26):2540, 2022. e-Pub 2022. PMID: 35767456.
- Guise TA, Wysolmerski JJ. Cancer-Associated Hypercalcemia. N Engl J Med 386(15):1443-1451, 2022. e-Pub 2022. PMID: 35417639.
- Trivedi T, Guise TA. Systemic effects of abnormal bone resorption on muscle, metabolism, and cognition. Bone 154:116245, 2022. e-Pub 2021. PMID: 34718221.
- Trivedi T, Pagnotti GM, Guise, TA, Mohammad KS. The Role of TGF-β in Bone Metastases. Biomolecules 11(11), 2021. e-Pub 2021. PMID: 34827641.
- Brown JE, Wood SL, Confavreux C, Abe M, Weilbaecher K, Hadji P, Johnson RW, Rhoades JA, Edwards CM, Croucher PI, Juarez P, El Badri S, Ariaspinilla G, D'Oronzo S, Guise TA, Van Poznak C. Management of bone metastasis and cancer treatment-induced bone loss during the COVID-19 pandemic: An international perspective and recommendations. J Bone Oncol 29:100375, 2021. e-Pub 2021. PMID: 34131559.
- Nagata Y, Miyagawa K, Ohata Y, Petrusca DN, Pagnotti GM, Mohammad KS, Guise TA, Windle JJ, David Roodman G, Kurihara N. Increased S1P expression in osteoclasts enhances bone formation in an animal model of Paget's disease. J Cell Biochem 122(3-4):335-348, 2021. e-Pub 2021. PMID: 33107091.
- Patterson AM, Wu T, Chua HL, Sampson CH, Fisher A, Singh P, Guise TA, Feng H, Muldoon J, Wright L, Plett PA, Pelus LM, Orschell CM. Optimizing and Profiling Prostaglandin E2 as a Medical Countermeasure for the Hematopoietic Acute Radiation Syndrome. Radiat Res 195(2):115-127, 2021. e-Pub 2021. PMID: 33302300.
- Guise TA. KCA RCC Bone Study. International Kidney Cancer Symposium (IKCS).
Review Articles
- Hamidi, S, Maniakas, A, Akhave, NS, Banuchi, VE, Busaidy, NL, Dadu, R, Ferrarotto, R, Guise, TA, Hofmann, M, Hosseini, SM, Hu, MI, Iyer, PC, Mansour, M, Marczyk, VR, Roy Chowdhuri, S, Sherman, SI, Sousa, LG, Wang, RJ, Williams, MD, Zafereo, M, Waguespack, SG, Cabanillas, ME. Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues. Journal of Clinical Endocrinology and Metabolism 111(2):471-483, 2026. e-Pub 2026. PMID: 40568752.
- Iyer, PC, Kikani, NJ, Khan, S, Chaudhari, A, Pagnotti, GM, Best, CJ, Weitzman, SP, Mehta, PB, Lavis, VR, Thosani, S, Gandhi, A, Aguirre, RS, Varghese, J, Guise, TA, Dadu, R. The evolving management of endocrine disorders induced by checkpoint inhibitors. Expert Review of Endocrinology and Metabolism 21(1):29-41, 2026. e-Pub 2026. PMID: 41307239.
- Hadji, P, Aapro, M, Al-Dagri, N, Alokail, M, Biver, E, Body, JJ, Brandi, ML, Brown, JE, Confavreux, C, Cortet, B, Drake, M, Ebeling, PR, Eriksen, EF, Fuleihan, GH, Guise, TA, Harvey, NC, Kurth, A, Langdahl, BL, Lems, W, Matijevic, R, McCloskey, EV, Nappi, R, Palacios, S, Pfeiler, G, Reginster, JY, Rizzoli, R, Santini, D, Tuzun, S, Poznak, CV, Villiers, TD, Zillikens, Mc, Coleman, R. Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer. Journal of Bone Oncology 53, 2025. e-Pub 2025. PMID: 40726588.
- Nebgen DR, Domchek SM, Kotsopoulos J, de Hullu JA, Crosbie EJ, Paramanandam VS, Brood-van Zanten MMA, Norquist BM, Guise TA, Rozenberg S, Kurian AW, Pederson HJ, Yuksel N, Michaelson-Cohen R, Bober SL, da Silva Filho AL, Johansen N, Guidozzi F, Evans DG, Menon U, Kingsberg SA, Powell CB, Grandi G, Marchetti C, Jacobson M, Brennan DJ, Hickey M. Care after premenopausal risk-reducing salpingo-oophorectomy in high-risk women: Scoping review and international consensus recommendations. BJOG 130(12):1437-1450, 2023. e-Pub 2023. PMID: 37132126.
- Ballinger TJ, Thompson WR, Guise TA. The bone-muscle connection in breast cancer: implications and therapeutic strategies to preserve musculoskeletal health. Breast Cancer Res 24(1):84, 2022. e-Pub 2022. PMID: 36419084.
- Handley NR, Feng FY, Guise TA, D'Andrea D, Kelly WK, Gomella LG. Preserving Well-being in Patients With Advanced and Late Prostate Cancer. Urology 155:199-209, 2021. e-Pub 2020. PMID: 33373704.
- Pagnotti GM, Thompson WR, Guise, TA, Rubin CT. Suppression of Cancer-associated bone loss through dynamic mechanical loading. Bone 150:115998, 2021. e-Pub 2021. PMID: 33971314.
- Hussain A, Tripathi A, Pieczonka C, Cope D, McNatty A, Logothetis C, Guise TA. Bone health effects of androgen-deprivation therapy and androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 24(2):290-300, 2021. e-Pub 2021. PMID: 33028943.
Abstracts
- Pagnotti GM, John SK, Trivedi T, Wilson RG, She Y, Wright LE, Murthy S, Suresh S, Rubin CT, Thompson WR, Mohammad KS, Guise TA. Low Intensity Vibration Combined with Zoledronic Acid Improves Bone Mass and Fracture Resistance in Completely Estrogen-Deprived Mice. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Pagnotti GM, Willis M, Trivedi T, Murthy S, John SK, She Y, Suresh S, Rubin CT, Thompson WR, Mohammad KS, Guise TA. Low Magnitude Mechanical Signals Enhance the Effects of Zoledronic Acid to Reduce Osteolytic Lesion Area and Improve Cardiac Function in a Murine Model of Breast Cancer Bone Metastases. American Society for Bone and Mineral Research.
- Trupti T, Laura W, Sutha J, Sukanya S, Sreemala M, Pagnotti Gabriel M, Yun S, Khalid M, Guise TA. Musculoskeletal and metabolic responses to low fat and high fat diet in athymic nude mice. Joint Meeting for the Cancer and Bone Society and American Society for Bone and Mineral Research Annual Conference.
- Trivedi T, Manaa M, John S, Reiken S, Pagnotti GM, Murthy S, Dole N, She Y, Suresh S, Hain B, Regan J, Ofer R, Wright L, Robling A, Cao X, Alliston T, Marks A, Waning D, Mohammad KS, Guise TA. Zoledronic Acid Improves Bone Quality and Muscle Function in High Bone-Turnover State. Joint Meeting for the Cancer and Bone Society and American Society for Bone and Mineral Research.
- Marks A, Wright L, Sutha J, Yun S, Mohamed M, Steven R, Pagnotti GM, Regan J, Trupti T, Ofer R, Guise TA, Sukanya S, Sreemala M, Tamara A, Cao X, Mohammad K, Robling A, Hain B, Waning D, Dole N. Zoledronic Acid Improves Bone Quality and Muscle Function in High Bone-Turnover State.
- Wright, Christian S, Semon KM, Kelly M, Yi X, Pagnotti GM, Hum JM, Robling AG, Frach-Carson MC, R Thompson AW. Deletion of the Auxiliary alpha 2 delta 1 Voltage-Sensitive Calcium Channel Subunit Increases Bone Marrow Adiposity in Mice. American Society for Bone and Mineral Research.
- Mohammad KS, Sreemala M, Sutha J, Reiken S, Bahrami A, Tersev S, Marks A, Cao X, Sukanya S, Evans-Molina C, Trupti T, Yun S, Pagnotti GM, Rojas J, Guise TA, Regan J. Bone-derived TGF- impairs glucose metabolism and insulin release by oxidation of RyR2 Ca2+ release channel in pancreatic-cells. Internal Medicine research retreat.
- Yun S, Tersev S, Cao X, Bahrami A, Sutha J, Rojas J, Murthy S, Mohammad K, Marks A, Regan J, Pagnotti GM, Trupti T, Sukanya S, Guise TA, Reiken S, Evans-Molina C. Excess TGF-b and high fat diet exacerbate musculoskeletal and metabolic complications of pathologic bone remodeling. Presented at Translating Energy Balance From Bench to Communities: Application of Parallel Animal-Human Studies in Cancer.
- Bagheri-Yarmand R, Martinez L, Song JH, Pagnotti GM, Martinez JA, Kuo TT, Lin S, Trivedi T, Mohammad KS, Guise TA. RET Promotes Osteoblastic Bone Metastases in Medullary Thyroid Cancer.
- Pagnotti G, Bacha DS, Kuo T, Trivedi T, Murthy S, Suresh S, Rubin CT, Thompson WR, Mohammad KS, Guise TA. Low Intensity Vibrations Combined with Zoledronic Acid Reduce Osteolytic Lesion Area from Breast Cancer Bone Metastases. The American Society for Bone and Mineral Research.
- Bacha D, Patil M, Guise TA. Denosumab Withdrawal in the Setting of Prostate Cancer Bone Metastasis is Associated with Hypercalcemia and Tumor Progression. American Society for Bone and Mineral Research.
- Deepika F, Patil M, Cabanillas ME, Guise TA. Severe Hypercalcemia Following Denosumab Withdrawal in Giant Cell Tumor of Bone: A Double-edged Sword Treatment Paradigm?. Endocrine Society.
- Bagheri-Yarmand R, Pagnotti GM, Guise TA. RET promotes osteoblastic lesions in medullary thyroid carcinoma bone metastasis by increasing osteoblast differentiation inhibited by small-molecule ONC201. American Thyroid Association.
- Shi L, Kuo T, Martinez J, Suresh S, Van V, Pagnotti G, Trivedi T, Bacha DS, Guerra L, Xu C, Guise TA. Excess TGF-ß is associated with cardiac dysfunction due to oxidative of RyR, Ca2+ leak and mitochondrial dysfunction. American Society for Bone and Mineral Research.
- Bagheri-Yarmand R, Pagnotti GM, Trivedi T, Martinez L, Martinez J, Kuo TT, Guerra LD, Song JH, Lin S, Guise TA. Role of RET in the pathogenesis of osteoblastic bone metastases due to medullary thyroid cancer. American Society for Bone and Mineral Research.
- Trivedi T, Bacha D, He W, John S, Murthy S, Suresh S, Pagnotti G, She Y, Mohammad K, Guise T. Sex-based Differential Response of Long-term High Fat Diet to Energy Metabolism, Musculoskeletal and Cardiac Function in Aged Mice. American Society for Bone and Mineral Research.
- Bagheri-Yarmand R, Pagnotti GM, Trivedi T, Guerra L, Kidd JL, Martinez JA, Song JH, Lin S, Guise TA. Bone-derived excess TGF-ß release is associated with cognitive dysfunction due to oxidation of RyR, Ca2+ leak and mitochondrial dysfunction. Cancer and Bone Society Annual Meeting.
- Trivedi T, Pagnotti GM, Suresh S, She Y, Murthy S, Martinez J, Molina C, Mohammad KS, Guise TA. Complete estrogen-deprived athymic nude mice are susceptible to changes in metabolism and musculoskeletal function mediated by a high-fat-diet. Cancer and Bone Society Annual Meeting.
- Patil M, Wangsirichareon S, Lazar A, Guise TA. Etiology Of Hypophosphatemia In A Patient With Co-existing Mesenchymal Tumor And Fibrous Dysplasia. Endocrine Society.
- Patil M, Wang Z, Thosani SN, Bassett RL, Guise TA. Denosumab Withdrawal Is Associated With Hypercalcemia In Adults With Osteoporosis And Bone Metastases. Endocrine Society.
- Shi L, Suresh S, Kuo T, Singh A, Martinez J, Trivedi T, Pagnotti GM, Guerra LD, Cao X, Guise TA. Bone-derived excess TGF-ß release is associated with cognitive dysfunction due to oxidation of RyR, Ca2+ leak and mitochondrial dysfunction. American Association For Cancer Research.
- Shi L, Kuo T, Martinez J, Suresh S, Trivedi T, Pagnotti GM, Guerra LD, Cao X, Guise TA. Bone-derived TGF-ß release is associated with cardiac dysfunction due to oxidation of SR calcium gatekeepers, Ca2+ leak and mitochondrial dysfunction. American Association For Cancer Research.
- Pagnotti GM, Touray A, Wan X, Guise TA. Low Intensity Vibration Attenuates Local and Systemic Bone Loss in Myeloma-Bearing Mice Treated with Proteosome Inhibitor. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Yarmand RB, Kidd JL, Pagnotti GM, Trivedi T, Guerra L, Martinez JA, Wan X, Song JH, Lin S, Guise TA. Activating RET mutations promotes osteoblastic bone metastasis by inhibiting osteoclastogenesis and stimulating osteoblast activity via regulation of osteoprotegerin. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Yarmand Rb, Kidd JL, Pagnotti GM, Trivedi T, Guerra L, Martinez JA, Wan X, Song JH, Lin S, Guise TA. Activating RET mutations promotes osteoblastic bone metastasis by inhibiting osteoclastogenesis and stimulating osteoblast activity via regulation of osteoprotegerin. American Association For Cancer Research.
- Wan X, Corn P, Wang J, Labanca E, Fing E, Pagnotti Gm, Yuan S, Shi L, Troncoso P, Logothetis C, Navone N, Guise TA. Dovitinib Mitigated Prostate Cancer Bone Metastases via Inhibiting the FGF Pathway. Cancer and Bone Society Conference.
- Yarmand RB, Kidd JL, Pagnotti GM, Trivedi T, Guerra L, Martinez JA, Wan X, Song JH, Lin S, Guise TA. Activating RET Mutations Promotes Osteoblastic Bone Metastasis by Stimulating Osteoblast Activity and Inhibiting Osteoclastogenesis via Regulation of Osteoprotegerin. American Society for Bone and Mineral Research.
- Yuan S, Wan X, Dadbin A, Hofmann MC, Guise TA. Anaplastic thyroid cancer bone metastases: Mechanistic insight from mouse models. American Thyroid Association Annual Meeting.
- Wan X, Corn P, Pagnotti GM, Yuan S, Guise TA. Dovitinib Mitigated Prostate Cancer Bone Metastases via Inhibiting the FGF Pathway. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Yuan S, Wan X, Dadbin A, Hofmann MC, Guise TA. Zoledronate prevents anaplastic thyroid cancer bone metastases: Mechanistic insight into ATC-bone interactions. American Thyroid Association Annual Meeting.
- Schuman C, Pagnotti GM, Guise TA, Schilling B. Countering Metastatic Breast Cancer in Bone with Combined Therapies Investigated via Proteomics of Formalin-Fixed Paraffin Embedded Tissues. American Society for Mass Spectrometry.
- Pagnotti GM, Dadbin A, Touray AF, Wang X, Wan X, Guise TA. Low-Intensity Vibration Preserves Musculoskeletal and Cardiac Function While Maintaining Survival During Bortezomib Therapy in Multiple Myeloma. The University of Texas MD Anderson Cancer Center.
- GM Pagnotti, Dadbin A, Touray AF, Wang X, Wan X, Guise TA. Low Intensity Vibration Preserves Musculoskeletal and Cardiac Function and Conserves Survival in Multiple Myeloma-Bearing Mice Under Bortezomib Therapy. American Society for Bone and Mineral Research.
- Wan X, Corn P, Yang J, Labanca E, Pagnotti GM, Yuan, Guise TA. Targeting FGF Signaling with Dovitinib to Suppress Prostate Cancer Bone Metastases. DoIM Research Retreat.
- Schuman C, Pagnotti GM, Guise TA, Schilling B. Proteomics of Bone Carrying Metastatic Breast Cancer Lesions from Archival Formalin-Fixed Paraffin Embedded (FFPE) Tissue Blocks Unveils Striking Skeletal Remodeling. American Society for Bone and Mineral Research.
- Zhouyao H, Guise TA. MFSD14A Deficiency Reveals Distinct Changes in Bone Architecture and Osteoclast Function. The Gordon Research Conference on Ligand Recognition and Molecular.
- Zhouyao H, Guise TA. Defining an Ammonia–Bone Axis Using a CRISPR-Mediated Global Mfsd14a Knockout Mouse Model Haonan Zhouyao1 & Theresa. The University of Texas MD Anderson Cancer Center.
- Zhouyao H, Wang X, Pagnotti GM, Guise TA. MFSD14A Defines an Ammonium-Driven Bone Remodeling. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Zhouyao H, Wang X, Guise TA. A Transporter-Mediated Ammonium Axis Controls Osteoclast Function and Bone Remodeling. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Pagnotti GM, Dadbin A, Touray AF, Wang X, Wan X, Guise TA. Low Intensity Vibration Coupled with Proteasome Inhibitor Improves Survival and Mitigates Cardiac Dysfunction and Stems Bone Loss. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Yuan S, Wan X, Ding H, Xiao H, Hofmann MC, Guise TA. Bone-derived TGF-β contributes to anaplastic thyroid cancer bone metastases. The Lawrence Family Bone Disease Program of Texas Research Conference.
- Yuan S, Wan X, Ding H, Hofmann MC, Guise TA. Bone-derived TGF-β contributes to anaplastic thyroid cancer bone metastases. The University of Texas MD Anderson Cancer Center.
- Yang X, Zhouyao H, Yuan S, Wan X, Wang X, Pan T, Satcher RL, Guise TA. Reduced CDH1/E-cadherin Expression Is Associated with Bone-Adaptive Transcriptional Programs in Human Breast Cancer Bone Metastases. MD Anderson Cancer Center UTHealth Houston Graduate School of Biomedical Sciences.
- Zhouyao H, Wang X, Pagnotti GM, Guise TA. Severe reduction in trabecular bone mass following global deletion of MFSD14A. The American Society for Bone and Mineral Research (ASBMR).
- Guise TA. Countering Metastatic Breast Cancer in Bone with Combined Therapies Investigated via Proteomics of Formalin-Fixed Paraffin Embedded (FFPE) Tissues. World Human Proteome Organization (HUPO).
- Yuan S, Wan X, Wang X, Pagnotti GM, Ding H, Xiao H, Hofmann MC, Guise TA. Bone-Derived TGF-β Promotes Anaplastic Thyroid Cancer Bone Metastases: Therapeutic Effects of Zoledronate and Bone-Targeted TGF-β Inhibition on ATC-Bone-Immune Microenvironment. American Society for Bone and Mineral Research.
- Yang X, Zhouyao H, Yuan S, Wan X, Wang X, Pan T, Satcher RL, Guise TA. Reduced CDH1 Expression Is Associated with Enhanced Tumor-Bone Remodeling Gene Profile in Human Breast Cancer Bone Metastases. American Society for Bone and Mineral Research.
Book Chapters
- Loots, GG, Guise, TA. Mechanisms Underlying Osteolytic and Osteoblastic Bone Metastases, 17-35, 2024.
- Joseph D, Guise TA. Approach to the patient with hypercalcemia. In: Oxford Textbook of Clinical Nephrology. Fourth. Oxford Prss, 2015.
- Clines GA, Guise TA. Hypercalcemia of malignancy. In: Medical Care of Cancer Patients. Peoples Medical Publishing House, 188-193, 2009.
- Heras-Herzig A, Kozlow W, Brown S, Guise TA. Osteoporosis associated with cancer and cancer treatment. In: Osteoporosis. Third. Academic Press, 1337-1374, 2008.
- Bartholin L, Guise. TGF-β in breast cancer osteolysis. In: TGF-β in Health and Disease, 2007.
- Clines GA, Guise TA. Mechanisms of bone destruction and bone formation by metastatic tumors. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth. American Society for Bone and Mineral Research, 2006.
- Heras-Herzig A, Guise TA. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. Fourth. Kluwer Academic Publishers, 2006.
- Clines GA, Chirgwin JM, Guise TA. Skeletal complications of malignancy: Central role for the osteoclast. In: Topics in Bone Biology. Springer-Verlag, 151-174, 2005.
- Guise TA, Chirgwin JM. Biology of bone metastases. In: Diseases of the Breast. Third. Lippman, Morrow and Osborne, 1285-1296, 2004.
- Mohammad KS, Guise TA. Osteoblastic bone metastases. In: Bone Metastases. First. Chung, 2004.
- Clines GA, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fifth. American Society for Bone and Mineral Research, 251-253, 2003.
- Mundy GR, Yoneda T, Guise TA, Oyajobi B. Local factors in skeletal malignancy. In: Principles of Bone Biology. Second. Academic Press, 1093-1104, 2002.
- Guise TA. Therapy affecting bone resorption and deposition. In: Management of Metastatic Disease to the Musculoskeletal System. Quality Medical Publishing, 107-138, 2002.
- Bruder JA, Guise TA, Mundy GR. Disorders of calcium metabolism. In: Endocrinology and Metabolism. Fourth. McGraw Hill Book Company, 1079-1159, 2001.
- Mundy GR, Guise TA. Pathophysiology of bone metastasis. In: Cancer and the Skeleton. Martin Dunitz Ltd, 43-64, 2000.
- Guise TA, Mundy GR. Disorders of calcium homeostasis. In: The Kidney: Physiology and Pathophysiology. Third. Lippincott, Williams & wilkins, 1811-1839, 2000.
- Mundy GR, Guise TA. Biology of bone metastases. In: Diseases of the Breast. Second. Lippman, Morrow and Osborne, 911-920, 1999.
- Mundy GR, Yoneda T, Guise TA. Hypercalcaemia in hematologic malignancies and in solid tumors associated with extensive localized bone destruction. In: Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Fourth. Lippincott Williams & Wilkins, 208-212, 1999.
- Guise TA, Mundy GR. Disorders of calcium metabolism. In: Therapy of Renal Diseases and Related Disorders. 3rd. Kluwer Academic Publishers, 85-114, 1997.
Letters to the Editor
- Kiel, DP, Guise, TA, Styner, M, Rubin, J. Concerns about the paper, “Benefits of targeted vibration for bone strength and bone density in postmenopausal women with osteopenia. JBMR Plus 9, 2025.
Patents
- Yoneda T, Mundy GR, Guise TA. Method to ameliorate osteolysis and metastasis. Patent Number: 5,993,817.
Patient Reviews
CV information above last modified September 16, 2026